{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:30:16Z","timestamp":1782707416535,"version":"3.54.5"},"reference-count":9,"publisher":"Wiley","issue":"15","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Few strategies exist for treatment of patients with small\u2010cell lung cancer (SCLC) extended\u2010stage after failure of first\u2010line platinum\u2010based chemotherapy. Lurbinectedin is a novel RNA\u2010polymerase\u2010II inhibitor investigated as a second\u2010line therapy for SCLC. However, its efficacy and safety profile in real clinical practice remain to be determined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the efficacy and safety of lurbinectedin in real\u2010life among patients with SCLC previously treated with first\u2010line platinum\u2010based chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively evaluated patients who received at least one dose of lurbinectedin (3.2\u00a0mg\/m<jats:sup>2<\/jats:sup>) between March 2020 and November 2021, in the pulmonary department of Bordeaux University Hospital. Endpoints were time to treatment discontinuation, progression\u2010free survival, overall survival, and safety profile.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirteen patients were included. The median age was 60\u2009years (range: 42\u201377), seven (54%) were females, nine (69%) having a performance status of 0\u20131. Lurbinectedin was given as second\u2010line treatment before platinum rechallenge in four (31%) patients. After a mean follow\u2010up of 4.1\u00a0months, the objective response rate (ORR) was 17%. The median time to treatment discontinuation (TTD) was 2.3\u00a0months (interquartile range [IQR], 1.2\u20133.6). The median progression\u2010free survival (PFS) and overall survival (OS) were, respectively, 1.9 (IQR, 0.1.8) and 4.1 (IQR, 2.0\u20133.5) months. No significant difference regarding TTD, PFS or OS was found in the two groups according to treatment history or according to chemotherapy\u2010free intervall (CMI) \u23291 or \u232a1 month. The most common adverse events (AEs) were asthenia, nausea, and anemia in nine (70%) patients. Grade 3 AEs were reported, fatigue, vomiting, nausea, anorexia, and neutropenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Lurbinectedin in real clinical practice could have had a lower efficacy than in phase II trial, but a better hematological and bioclinical tolerance than previously reported. Early relapse after platinum\u2010based chemotherapy seems to have a lower response to lurbinectedin.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.14464","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T05:39:30Z","timestamp":1655530770000},"page":"2248-2252","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Second\u2010line lurbinectedin as a new treatment option for small\u2010cell lung cancer: Preliminary results in real\u2010clinical practice"],"prefix":"10.1111","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8224-5279","authenticated-orcid":false,"given":"Anne\u2010Claire","family":"Toublanc","sequence":"first","affiliation":[{"name":"Pulmonary Department, P\u00f4le Cardio\u2010thoracique CHU de Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Guecamburu","sequence":"additional","affiliation":[{"name":"Pulmonary Department, P\u00f4le Cardio\u2010thoracique CHU de Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Veillon","sequence":"additional","affiliation":[{"name":"Pulmonary Department, P\u00f4le Cardio\u2010thoracique CHU de Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Rosellini","sequence":"additional","affiliation":[{"name":"Pulmonary Department, P\u00f4le Cardio\u2010thoracique CHU de Bordeaux  Bordeaux France"},{"name":"INSERM, Centre de Recherche Cardio\u2010Thoracique de Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre\u2010Olivier","family":"Girodet","sequence":"additional","affiliation":[{"name":"Pulmonary Department, P\u00f4le Cardio\u2010thoracique CHU de Bordeaux  Bordeaux France"},{"name":"INSERM, Centre de Recherche Cardio\u2010Thoracique de Bordeaux  Bordeaux France"},{"name":"Centre de Recherche Cardio\u2010thoracique de Bordeaux Univ\u2010Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Zysman","sequence":"additional","affiliation":[{"name":"Pulmonary Department, P\u00f4le Cardio\u2010thoracique CHU de Bordeaux  Bordeaux France"},{"name":"INSERM, Centre de Recherche Cardio\u2010Thoracique de Bordeaux  Bordeaux France"},{"name":"Centre de Recherche Cardio\u2010thoracique de Bordeaux Univ\u2010Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30068-1"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep15437"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2015.04.006"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt178"},{"key":"e_1_2_7_9_1","volume-title":"NCCN clinical practice guidelines in oncology. Small cell lung cancer","author":"Oncology National Comprehensive Cancer Network","year":"2019"},{"key":"e_1_2_7_10_1","unstructured":"MonnetI BaizeN GreillierL et al.Carboplatin\u2010etoposide versus topotecan as second\u2010line treatment for sensitive relapsed small\u2010cell lung cancer: phase 3 trial (ID 546) IASLC. 2019 World Conference on Lung Cancer; Barcelona Spain; Sept 7\u201310 2019(abstr OA15.02)"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.14464","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1759-7714.14464","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.14464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:24:22Z","timestamp":1692836662000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.14464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":9,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/1759-7714.14464"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.14464","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"2022-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}